> **Spec vs implementation:** this file is the original aspirational product-spec
> text. The shipped module is deterministic/statistical/mechanistic computation
> (PWMs, ODEs, published vendored models, heuristics) - NOT a trained deep
> learning, foundation, GNN, or RL model, whatever the text below says. See
> STATUS.md for what is actually verified.

# Liquid Biopsy

Liquid Biopsy: An AI-enhanced detection system for circulating tumor DNA, improving the sensitivity of early-stage cancer diagnosis through deep learning noise filters. It suggests optimal biomarkers and provides simulated raw vs. filtered signal visualizations. Liquid Biopsy offers a non-invasive method for monitoring disease progression and treatment response from blood.






Liquid Biopsy
Liquid Biopsy is an AI-enhanced molecular diagnostics platform that detects and reconstructs tumor-derived signals from circulating biomarkers in blood, enabling ultra-early cancer detection and longitudinal disease monitoring. The system processes circulating tumor DNA (ctDNA), cell-free DNA, exosomal RNA, and protein biomarkers from blood samples, treating the plasma environment as a highly noisy stochastic signal space where rare tumor-derived fragments must be extracted from overwhelming normal background signals.
Sequence signal denoising is performed using transformer-based deep learning models trained on large-scale genomic datasets. These models distinguish true somatic mutations from sequencing errors, PCR artifacts, and biological noise by learning contextual dependencies across genomic fragments. Probabilistic filtering layers estimate confidence scores for each detected variant, enabling ultra-sensitive mutation detection even at extremely low allele frequencies.
Reconstruction of tumor genomic architecture is achieved through Bayesian haplotype inference and fragment assembly algorithms that reconstruct partial tumor genomes from fragmented circulating DNA. This enables identification of somatic mutations, copy number variations, structural rearrangements, and epigenetic modifications. Longitudinal sampling allows tracking of tumor evolution, clonal expansion, and treatment-induced selection pressure over time.
Multi-omics integration enhances diagnostic resolution by combining ctDNA data with methylation signatures, proteomic markers, and metabolomic profiles. Machine learning models identify composite biomarker signatures that correlate strongly with early-stage cancer presence, tissue of origin, and disease progression risk. This improves both sensitivity and specificity compared to single-modal diagnostics.
Finally, Liquid Biopsy outputs clinically interpretable diagnostic reports including cancer probability scores, tumor origin classification, progression risk trajectories, and treatment response indicators. Visualization tools provide raw versus denoised signal comparisons, mutation heatmaps, and longitudinal tracking dashboards, enabling continuous, non-invasive monitoring of disease dynamics over time.
